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Abstract
Introduction: The objective was to characterize the clinical and myopathologic features of patients with
scleroderma-polymyositis (SSc-PM) overlap compared with a population of patients with systemic sclerosis (SSc) and
polymyositis (PM).
Methods: A three-way comparison of patients with SSc-PM overlap (n = 25) with patients with SSc (n = 397) and
PM (n = 40) on clinical and myopathologic features and causes of death. One neuropathologist blinded for the
diagnosis evaluated all recent available muscle biopsies. Biopsies were scored for presence of inflammation,
necrotic muscle fibers, rimmed vacuoles, fibrosis, and immunohistochemical staining. Clinical or myopathologic
characteristics were compared by using the χ2 test or one-way analysis of variance (ANOVA).
Results: The prevalence of SSc-PM overlap in the Nijmegen Systemic Sclerosis cohort was 5.9%. The mortality was
32% (eight of 25) in SSc-PM, of which half was related to cardiac diseases. The prevalence of pulmonary fibrosis was
significantly increased in SSc-PM (83%) (P = 0.04) compared with SSc (49%) and PM (53%). SSc or myositis-specific
antibodies were nearly absent in the SSc-PM group. In almost all biopsies (96%) of SSc-PM patients, necrotic muscle
fibers were present, which was significantly increased compared with PM patients (P = 0.02).
Conclusions: Patients with SSc-PM have increased prevalence of pulmonary fibrosis and cardiac disease as the
cause of death compared with patients with SSc and PM . In addition, we found that necrotizing muscle fibers with
inflammation characterize SSc-PM overlap in muscle biopsies. Further research should focus on underlying
mechanisms causing necrosis, inflammation, and fibrosis and their relation to pulmonary involvement and mortality
in patients with SSc-PM overlap.
Introduction
Systemic sclerosis (SSc) is a systemic autoimmune disease
characterized by vascular lesions and fibrosis of multiple
organs, predominantly in skin, lungs, heart, intestinal tract,
joints, and muscles [1,2]. The prevalence of myopathies in
SSc patients varies from 5% to 81%, depending on the use
of different definitions of muscle involvement [3-11]. Myo-
sitis in SSc patients resembles clinical and biologic features
of patients with polymyositis (PM), hence the term sclero-
derma/polymyositis overlap (SSc-PM). Previous studies
demonstrated a worse survival and increased prevalence of
myocardial involvement in SSc-PM overlap compared with
SSc [9,12]. Therefore, it seems clinically relevant to identify
SSc-PM overlap for close monitoring and early treatment.
To date, no studies have been conducted to characterize
the full spectrum of SSc-PM overlap by means of a three-
way comparison with SSc and idiopathic PM. Better un-
derstanding of similarities and differences in clinical and
biologic features as well as outcome may lead to improved
treatment and prognosis for SSc-PM overlap patients.
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The aim of this study is to characterize the clinical and
myopathologic features of patients with SSc-PM overlap
patients compared with a population of patients with SSc
and PM.
Methods
Design
The Nijmegen Systemic Sclerosis cohort is an ongoing,
prospective inception cohort started in 1989 at the Depart-
ment of Rheumatic Diseases at the Radboud University
Medical Center. The data collection contains information
of symptoms, physical examination, laboratory workup, as
well as annually performed pulmonary-function test re-
sults, echocardiography, right-heart catheterization, and
high-resolution computed tomography (HRCT) scans at
baseline and when indicated.
The Nijmegen Myositis cohort is also a prospectively
followed-up cohort of patients with inflammatory myop-
athies. This cohort includes all patients with inflammatory
myopathies from the Computer Registry of All Myopathies
and Polyneuropathies (CRAMP) treated at the Radboud
University Medical Center [13]. The CRAMP is a Dutch
multicenter neuromuscular registry and was developed in
2004. The data available of the Nijmegen Myositis cohort
consist of demographic and clinical features at diagnosis
combined with follow-up information on treatment, bio-
chemical markers, pulmonary-function test results, and, if
indicated, HRCT scans and echocardiography.
Participants
All patients with SSc can be classified by the ACR prelim-
inary classification criteria for SSc or Leroy criteria for
early SSc. The patients with PM all fulfilled the Bohan and
Peter diagnostic criteria, whereas the SSc-PM overlap par-
ticipants fulfilled both criteria [14-17].
All SSc-PM patients of the Nijmegen Systemic Sclerosis
cohort were included. SSc patients with serum CK more
than 2 times upper limit, myalgia, and proximal muscle
weakness were analyzed for the presence of polymyositis
with electromyography (EMG) and muscle biopsy. All
consecutive PM patients of the Nijmegen Myositis cohort
were included. The study was exempted from approval of
the local Medical Ethics Committee Arnhem-Nijmegen in
the Netherlands, because this was an observational, nonin-
terventional study. Therefore, no informed consent was
required for this study.
Myopathologic analysis
The slides of all available muscle biopsies of SSc-PM (n =
24) and most-recent consecutive patients with PM (n = 24)
were used to pair with a 1:1 ratio. One neuropathologist
(ML), blinded for diagnosis, evaluated all muscle biopsies.
Biopsies were scored for the presence of inflammatory in-
filtrates, necrotic muscle fibers, fibrosis, rimmed vacuoles,
and, if performed for enzyme histochemistry, for cyto-
chrome C-oxidase (COX) and succinate dehydrogenase
(SDH) and immunohistochemistry for MHC class I, mem-
brane attack complex (MAC), CD 4, CD 8, CD 20, and
CD 68. Inflammatory infiltrates were defined as the pres-
ence of mononuclear cell infiltrates surrounding or invad-
ing muscle fibers. Necrosis in muscle biopsy was defined
as presence of acute necrotic muscle fibers, identified on
hematoxylin–phloxine staining (paling of the cytoplasm
and absence of basophilia), myophagia, or the presence of
regenerating basophilic fibers. Fibrosis was defined as in-
crease of collagen and fibroblasts in the endomysium.
MHC class I upregulation was regarded as positive if at
least the sarcolemma expressed MHC class I antigen [18].
MAC upregulation was regarded as present if MAC was
expressed in the endothelium of capillaries or in the sarco-
plasm of muscle fibers [19,20].
Statistical analysis
Statistical analysis was performed with SPSS version 20 for
Windows (SPSS Inc., Chicago, IL, USA). Study population
and muscle-biopsy characteristics were compared with the
χ2 test or Fisher Exact test for nominal data and the
Mann–Whitney U test for numeric data or one-way
ANOVA. Statistical significance was defined as P ≤ 0.05.
Results
The mean age at diagnosis was 53 years (SD, 12.3) (SSc-
PM overlap), 50 years (SD, 13.2) (SSc), and 51 years (SD,
16.5) (PM). The median disease duration was 5.0 years
(IQR, 2.8 to 12.4), 7 years (IQR, 3 to 14), and 3.5 years
(IQR, 2 to 11), respectively. The SSc-PM group was char-
acterized by an almost 1:1 female/male ratio, whereas the
SSc group by 2:1 female-to-male ratio, and the PM group
by an almost opposite ratio of 1:2 (Table 1). The prevalence
of SSc-PM overlap in the Nijmegen Systemic Sclerosis co-
hort was 5.9%.
Serology
SSc-specific autoantibodies (anticentromere and antitopoi-
somerase 1), were nearly absent in the SSc-PM group and
present in 19% and 22% of the SSc patients. None of the
PM patients tested positive for anticentromere and antito-
poisomerase 1, except one PM patient. Myositis-associated
antibody, anti-SSA and myositis-specific antibody, anti-
Jo1, were significantly less present in the SSc-PM group
compared with the PM groups (Table 1).
Scleroderma and myositis-specific features
Raynaud phenomenon was present in all groups: 21 pa-
tients (84%) in SSc-PM overlap, 379 patients (96%) in
SSc, and 13 patients (33%) in PM. The 13 (33%) patients
with Raynaud phenomena in the PM group also had fea-
tures such as mechanic hands, arthritis, ILD, and were
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Table 1 Study population characteristics
Characteristics Number SSc-overlap (n = 25) Number SSc (n = 397) Number PM (n =40) P value
Age in years, mean (SD) 25 53 (12.3) 397 50 (13.2) 40 51 (16.5) 0.013
Gender (male/female) 25 12/13 397 131/266 40 25/15 0.003
Type diagnosis
Limited cutaneous 19 (76%) 276 (73%) NA NS
Diffuse cutaneous 6 (24%) 109 (27%)
Disease duration, years median (IQR) 25 5 (3–12) 397 7 (3–14) 40 3.5 (2–11) 0.001
Mortality 25 8 (32%) 397 65 (16%) 40 7 (18%) NS
Survival in years, median (IQR) 8 2.5 (1.3-9.6) 65 7 (3–13.5) 7 0.3 (0–12) NS
Serology
ANA 25 25 (100%) 397 356 (90%) 34 21 (62%) 0.006
Anti-topoisomerase 21 0 397 87 (22%) 31 1 (3%) 0.048
Anti-centromere 19 2 (10%) 397 76 (19%) 31 0 NS
Anti-SSA 25 2 (8%) 397 15 (4%) 31 11 (36%) < 0.001
Anti-SSB 25 0 NA 31 1 (3%) NS
Anti-RNP 25 2 (8%) 397 27 (7%) 31 2 (6%) NS
Anti-SM 25 0 NA 31 2 (6%) NS
Anti-Jo1 25 2 (8%) NA 31 13 (42%) 0.013
NA, not applicable; NS, not significant.
Table 2 Disease-specific characteristics
Characteristics Number SSc-overlap (n = 25) Number SSc (n = 397) Number PM (n = 40) P value
Scleroderma features
Raynaud phenomena 25 21 (84%) 397 379 (96%) 40 13 (33%) <0.001
Digital ulcers 25 6 (24%) 397 164 (41%) 40 3 (8%) <0.001
Pitting scars - 397 160 (40%) NA NA
Rodnan skin score (median) 15 6 (5–11) 372 7 (4–12) NA NS
Renal crisis 25 1 (4%) 397 17 (4%) NA NS
Myositis features
Serum CK elevation‡ 25 24 (96%) 397 48 (12%) 40 34 (85%) <0.001
Proximal muscle weakness 25 25 (100%) 397 21 (5%) 40 37 (93%) <0.001
Myopathic EMG findings 25 22 (88%) NA 29 24 (83%) NS
Mechanic hands NA NA 40 7 (18%) NS
Internal complications
Arthritis 25 5 (20%) 397 46 (12%) 40 7 (18%) NS
Interstitial lung disease
HRCT fibrosis 18 15 (83%) 346 170 (49%) 19 10 (53%) 0.044
TLC ≤70% of predicted 21 4 (19%) 364 68 (19%) 23 9 (39%) NS
TLCO ≤70% of predicted 17 17 (100%) 347 260 (75%) 20 13 (65%) 0.001
Diastolic dysfunction by cardiac ultrasound 19 7 (37%) 352 146 (42%) 19 4 (21%) NS
PH suspicion by cardiac ultrasound 20 3 (15%) 352 89 (25%) 19 2 (11%) 0.042
PH by cardiac catherization 5 0 182 57 (31%) 2 1 (50%) 0.002
Myocarditis 25 1 (4%) NA 40 0 NS
Malignancy 25 2 (8%) NA 40 5 (13%) NS
NA, not applicable; NS, not significant; TLC, total lung capacity; HRCT, high-resolution CT scan; TLCO, transfer factor of the lung for carbon monoxide; PH,
pulmonary hypertension.
‡Defined >2 times upper limit of normal (ULN).
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anti-Jo1 antibodies positive, reflecting the anti-synthetase
syndrome. The median modified Rodnan skincore (mRSS)
was 6 (IQR, 5 to 11) in the SSc-PM group and 7 (IQR, 4
to 12) in the SSc group (Table 2).
Signs of myositis such as serum CK elevation (>2 times
ULN) and proximal muscle weakness were present in 48
SSc patients (12%) and in 21 SSc patients (5%), respect-
ively (Table 1). Arthritis was present in all three groups,
with a prevalence ranging from 12% to 20%.
Interstitial lung disease
Interstitial lung disease (ILD) was diagnosed in patients
whether or not moderate to severe pulmonary fibrosis
was present on the HRCT scan. The presence of ILD
was statistically significantly higher in the SSc-PM over-
lap group compared with the other two groups. Further-
more, a significantly higher prevalence of decreased lung
carbon monoxide diffusion capacity (defined as TLCO
≤70%) was found in the SSc-PM overlap group (Table 2).
Cardiac complications
Diastolic dysfunction on echocardiography was present in
all three groups. Right heart catheterization (RHC) was
performed only when pulmonary hypertension (PH) was
suspected at echocardiography or in cases with unex-
plained dyspnea or an isolated decrease of carbon monox-
ide (CO) diffusion capacity at pulmonary-function testing.
PH was diagnosed in none of the SSc-PM overlap patients,
in 57 SSc patients, and in one PM patient. When no RHC
was performed, we assumed that PH was absent. With this
assumption, we found a statistically significant increase of
PH in SSc patients compared with the other groups.
Malignancy
In the SSc-PM overlap group, one patient developed a
squamous cell carcinoma in the neck, and one patient de-
veloped a basal cell carcinoma of the skin on the forehead.
In five patients in the PM group, a malignancy was diag-
nosed during follow-up, consisting of renal cell carcinoma
(n = 1), melanoma (n = 1), breast cancer (n = 1), esophagus
carcinoma (n = 1), and lung carcinoma (n = 1). Data con-
cerning numbers and types of malignancy cases were not
available in the SSc group.
Mortality
Eight patients (32%) in the SSc-PM overlap group died,
which was not statistically significantly increased compared
with the other groups (Table 1). The causes of death
were progressive heart disease (n = 2), myocardial infarc-
tion (n = 2) , respiratory failure due to interstitial lung
disease (ILD) (n = 1) , sepsis (n = 2), and unknown cause
(n = 1). Causes of mortality in the SSc group were prog-
ressive heart failure (n = 7) 10.8%, myocardial infarction
(n = 2) 3.1%, respiratory failure due to ILD (n = 11) 16.9%,
or pulmonary hypertension (n = 13) 20%, malignancies
(n = 6) 9.2%, infections (n = 6) 9.2%, and other or un-
known causes (n = 20) 30.8%. In the PM group, seven
patients died. Their causes of death were progressive
heart disease (n = 2), aspiration pneumonia (n = 2), ma-
lignancy (n = 2), and unknown cause (n = 1).
Myopathology
All muscle biopsies were assessed by the same neuro-
pathologist who was blinded for the clinical diagnosis,
and his findings are shown in Table 3 and Figure 1. We
found a statistically significant difference in the presence
of necrotic muscle fibers, present in 96% of the SSc-PM
biopsies compared with 67% of the PM biopsies. This
significant difference was caused mostly by differences
in the presence of acute necrotic muscle fibers (50% ver-
sus 29.2%).
The presence of inflammatory markers such as lympho-
cytic infiltrates (63% versus 54%) and positive MHC I
staining (92% versus 78%) were not significantly different
among the SSc-PM overlap patients compared with the
PM patients. Fibrosis displayed quite similar rates of pres-
ence in both groups. None of the muscle biopsies revealed
rimmed vacuoles, ruling out inclusion-body myositis [21].
On characterization of different types of lymphocytes, only
limited data were available. Deposition of MAC was found
only in necrotic muscle fibers and not in the capillaries.
COX and SDH staining was more often applied on the
specimens and in a small number of cases (n = 3) in SSc-
PM and (n = 6) in PM revealed the presence of COX-
negative muscle fibers.
Discussion
In this study, we describe and compare both the clinical
characteristics and myopathologic findings of patients with
SSc-PM overlap, SSc and PM. We found an increased
prevalence of pulmonary fibrosis among patients with SSc-
PM overlap, which is in accordance with a Japanese study
that also showed an increased presence of ILD among pa-
tients with SSc-PM overlap compared with patients with
SSc [7]. However, an increased presence of ILD was not
confirmed in a French study [22]. ILD can cause early
death and can diminish the quality of life because of symp-
toms of dyspnea and fatigue. However, no significant dif-
ference was found in ILD-associated death between the
patients with SSc-PM overlap, SSc, and PM. However, our
study has only a small study population, which limits a
proper survival analysis with ILD. The increased preva-
lence of ILD in overlap patients should warrant regular
screening for this complication and timely initiation of spe-
cific immunosuppressive therapy. Further studies should
focus on the extent of pulmonary fibrosis and related mor-
bidity among SSc-PM patients.
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Several studies have described increased myocardial
involvement, such as diastolic or systolic dysfunction
and myocarditis, in patients with SSc-associated myop-
athies [7,9,22,23]. We found no statistically significant
difference in myocardial involvement between the three pa-
tient cohorts in our study, but we used echocardiography
as a screening tool, and cardiac MRI was not performed
routinely. Echocardiography lacks specificity to diag-
nose myocarditis accurately, so the prevalence of this
complication could prove to be higher if a cardiovascu-
lar MRI were performed as well [24]. In our cohort, we
found progressive heart disease to be the cause of death
Table 3 Myopathologic markers of muscle biopsy slides
Characteristics Number SSc-overlap (n = 24) Number PM (n = 24) Significance (P value)
Necrotic muscle fibers 24 23 (96%) 24 16 (67%) 0.023b†
Lymphocytic infiltrates 24 15 (63%) 24 13 (54%) NS
Positive MHC class I staining 12 11 (92%) 18 12 (67%) NS
Inflammationa 24 19 (79%) 24 18 (75%) NS
MAC staining 10 5 (50%) 13 5 (39%) NS
Fibrosis 19 5 (26%) 24 2 (8%) NS
Presence of COX-negative fibers 10 3 (30%) 10 6 (60%) NS
MAC, Membrane attack complex; NA, not applicable; NS, not significant.
aInflammation is defined as positive MHC class I staining or/and presence of lymphocytic infiltrates.
bStatistically significant.
Figure 1 Histopathologic muscle-biopsy images of SSc-PM overlap patient versus PM patient. Left side (A, C, E): SSc-overlap patient. Right
side (B, D, F): PM patient. (A) Hematoxylin & eosin (H&E) stain; upper marker, necrosis; lower marker, lymphocytic infiltrate; (B) H&E stain; marker,
lymphocytic infiltrate; (C) MAC stain; markers, MAC upregulation; (D) MAC stain, no upregulation; (b v 02D7; (E) MHC class I stain, sarcolemmal
MHC class I upregulation; (F) MHC class I stain, sarcolemmal and diffuse cytoplasmic MHC class I upregulation.
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in 25% of our overlap patients compared with only 10.8%
of SSc patients.
The prevalence of SSc-PM overlap in our Nijmegen Sys-
temic Sclerosis cohort was low (5.9%) compared with that
in older investigations [3-7,9]. In more-recent studies, prev-
alences of 7.6% and 7.2% [22,25] were observed, which is
comparable to our finding. This discrepancy in prevalences
compared with older studies can be explained by the differ-
ent criteria used to define SSc myopathy and the different
study designs. In our study, we used strict criteria to select
only inflammatory myopathies among SSc patients and not
associated myopathies. Furthermore, this investigation
includes only clinically relevant causes, whereas Medsger
et al. [3] reported 90% prevalence of proximal muscle
weakness, of which only 20% complained of muscle-
related symptoms.
Different antibodies are associated with SSc-PM over-
lap, such as anti-PM/Scl and anti-Ku [26,27]. More-
recent studies show novel antibodies related to SSc-PM,
anti-U3 RNP, and anti-RuvBL1/2, respectively [28,29].
These antibodies relate to different clinical manifesta-
tions of SSc-PM-overlap patients; for example, Caucasian
patients with limited cutaneous involvement and pul-
monary fibrosis (antiPM/Scl) or African male patients
with diffuse cutaneous involvement and pulmonary arter-
ial hypertension (anti-U3 RNP) [26,28]. Unfortunately, no
data concerning SSc-PM overlap-associated antibodies
were available, which can be regarded as a limitation of
our study.
We studied muscle biopsies of both overlap and PM pa-
tients, blinded for the diagnosis. For the first time, our
study revealed that the myopathology in patients with SSc-
PM overlap syndrome shows specific features compared
with PM patients. Necrotizing muscle fibers were observed
in almost all SSc-PM overlap samples. In the majority of
the SSc-PM muscle biopsies, features of inflammation
were also found, enabling us to exclude the histopathologic
diagnosis of a necrotizing myopathy, according to the
European Neuromuscular Centre workshop 2003 [30]. A
French study showed a slightly lower prevalence of 25
(63%) of 35 necrotic muscle fibers among their cohort of
SSc-PM overlap patients [8]. However, when including the
presence of regenerating (that is, basophilic) muscle fibers,
a feature present after necrosis, the prevalence of necrosis
is in accordance with our findings.
MAC staining is often used to analyze muscle biopsies
for signs of dermatomyositis (DM) if present as linear de-
posits at endothelial cells of endomysial capillaries [19,20].
This was not present in our study. We observed MAC
staining in the sarcoplasm, which is indicative of necrotic
fibers. No presence of rimmed vacuoles was found in this
study. This verifies that our PM muscle biopsies are homo-
geneous for that diagnosis and are unlikely to include pa-
tients with IBM or DM.
The presence of COX-negative muscle fibers might be
indicative of mitochondrial abnormalities. Growing evi-
dence suggests that mitochondrial abnormalities can be
found in dermatomyositis, inclusion-body myositis, and
very seldom in polymyositis [21,31]. The results of our
study revealed a small number of cases with COX-negative
fibers. Only two PM patients had more than a single af-
fected muscle fiber, but both patients were older than
65 years, and in these cases, the COX-negative fibers may
be considered an effect of ageing. Therefore, we conclude
that no evidence exists for mitochondrial pathology in pa-
tients with SSc-PM overlap.
This study has several limitations. All the subjects were
recruited from a single, tertiary referral center, which may
have led to a bias toward more-severe cases. However, this
is true for all three patient cohorts, and therefore, it would
less likely bias observed differences among the patient
cohorts. The small sample size of the SSc-PM overlap co-
hort makes us cautious about overinterpretation of results.
Nonetheless, by using strict criteria, we were able to
identify a well-defined homogeneous overlap cohort. Fur-
thermore, the blinded-for-diagnosis expert assessment of
overlap muscle biopsies in comparison with PM biopsies is
unique and greatly increased the strength of our findings.
Conclusions
In conclusion, we found a prevalence of 5.9% of SSc-PM
overlap in the Nijmegen Systemic Sclerosis cohort. Sec-
ond, we observed an increased proportion of pulmonary
fibrosis among patients with SSc-PM overlap. Third, we
revealed that cardiac complications are a major cause of
death in patients with SSc-PM overlap. Consequently, we
urge more active and regular cardiopulmonary screening
among these SSc-PM patients. Fourth, we found that nec-
rotizing muscle fibers with inflammation characterize SSc-
PM overlap in muscle biopsies. Further research should
focus on underlying mechanisms causing necrosis, inflam-
mation, and fibrosis and their relation to pulmonary in-
volvement and mortality in SSc-PM overlap patients to
optimize treatment, increase survival, and improve quality
of life.
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